Innovation has two lead drug candidates—Brilacidin and Kevetrin—with first-in-class potential in mid-to-late stage development that have proven safe and effective in treating a number of indications across various therapeutic areas.
As to Brilacidin, in the area of infectious disease, Acute Bacterial Skin and Skin Structure Infection (ABSSSI) is the target indication. Concerning gastrointestinal conditions, a proof-of-concept study has been completed successfully evaluating Brilacidin's immunomodulatory properties in treating Distal Colitis. The Company also has successfully completed a Phase 2 trial of Brilacidin in Oral Mucositis, aligning with the FDA on a planned Phase 3 program. In the area of cancer, the development emphasis is on Ovarian Carcinomas, a gateway indication toward Kevetrin treating many types of hematological malignancies and tumors.